openPR Logo
Press release

Tuberculosis Drugs Market High Funding for Research and Development and Growth by Pfizer Inc, Lupin Laboratories Ltd, AstraZeneca Plc, Cadila Pharmaceuticals, Novartis AG, Alkem Laboratories Ltd, and Cipla Ltd.

11-12-2018 11:55 AM CET | Health & Medicine

Press release from: Coherent Market Insights

Tuberculosis Drugs Market Industry

Tuberculosis Drugs Market Industry

Tuberculosis Drugs Market is expected to have a highly positive outlook for the next five years 2018–2026 according to a recently released Tuberculosis Drugs Market research report. The report has been added in his large database by Coherent Market Insights.”

The major takeaways in the report are product segment analysis, application segment analysis, regional segment analysis and data of the major Tuberculosis Drugs Market players from around the world. The report presents an introductory as well as detailed information about the Tuberculosis Drugs Market through a well-organized layout divided into easy to understand chapters.

Request a Sample Copy@ https://www.coherentmarketinsights.com/insight/request-sample/191

Tuberculosis is a deadly infectious disease that affects the lungs. Among diseases, tuberculosis is the second largest cause of death worldwide. Tuberculosis are broadly classified as latent tuberculosis and active tuberculosis. Globally around 10% of latent infections develop into active tuberculosis. Infections that do not show any symptoms are called latent tuberculosis. In 2015, the malady resulted in 1.8 million deaths and 10.4 million new reported cases. In 2015, in the U.S., there were 9,557 tuberculosis cases reported. Based on the statistics of Center for Disease Control and Prevention, a 1.6% increase in the number of tuberculosis cases was observed in 2015 as compared to those reported in 2014. Though there is an increase in the number of tuberculosis cases, the incidence rate per 100,000 persons has been around 3.0 since 2013.

Market Dynamics

Asia and Africa are the largest markets for tuberculosis drugs, as these regions have the highest prevalence of TB. There are many initiatives taken to control the TB increasing cases. The United Nations’ Millennium Development Goals have framed various strategies to reduce TB prevalence and death rates by 2015, which can be achieved by WHO’s Stop TB Strategy. According World Health Organization, in 2006, 61% out of 2.5 million new smear positive cases with DOTS, and are all the new smear cases on the year, and the treatment was successful in 85% cases. The estimated global incidence rate of tuberculosis shown decline rate by 0.6% in 2005 and 2006. In 2006, the incidence rate of tuberculosis became stable in the Europe and is declining gradually in the other WHO countries. World Health Organization has an approximation that the occurrence of tuberculosis and death rates are declining faster than the incidence rate.

Market Taxonomy

This report segments the global tuberculosis drugs market on the basis of therapy type and geography. On the basis of therapy type, the market is categorized into first line drugs, Second line drugs and combination drug therapy. Under First line drugs, the market is further segmented into drugs such as Isoninazid, Rifampicin, Ethambutol, Pryazinamide, and Strepromycin. The second line drugs are further segmented into Injectable, Fluoroquinolones, and Bacteriostatic Agents and Others. For comprehensive understanding of market dynamics, the global tuberculosis drugs market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Download PDF Brochure@ https://www.coherentmarketinsights.com/insight/request-pdf/191

There was around US$ 6.6 billion revenue accessible for tuberculosis care and prevention in many of the low and middle-income countries in 2016, out of which 84% was from domestic sources. However, national tuberculosis program (NTPs) in low income countries linger to depend on international donors or foreign healthcare agencies to fund them approximately 90%. Investments in low income countries and middle income countries declined by US$ 2 billion to US$ 8.3 billion, which was needed in 2016. There were many enhancements needed in overall healthcare financing to curb new tuberculosis cases proportionally boosting tuberculosis drugs market. Government expenditures on healthcare in specific to tuberculosis in 2014 were less than the World Health Organization set a benchmark of at least 6% of gross domestic product in around 150 countries. Private expenditures surpassed 45% of total healthcare expenditures in tuberculosis in 46 countries, which also includes 11 of the 30 high tuberculosis burden countries. Presently, there are around 13 vaccine candidates in clinical development, which include trial drugs for prevention of tuberculosis infection and trial drugs for prevention of tuberculosis disease in people with Latent Tuberculosis Disease. According to WHO, at least US$ 2 billion investment is needed every year for tuberculosis research and development. In stark contrast, capital investment during 2005–2014 was reported to be US$ 0.7 billion annually. Infusion of investments in research and development would significantly improve the tuberculosis drugs market outlook.

Detailed Segmentation:

Global Tuberculosis Drugs Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy
Global Healthcare Biometrics Market, By Geography:
North America
U.S.
U.S. Tuberculosis Drug Market, By Therapy Type:
First Line Drugs Therapy
Second Line Drugs Therapy
Combination Drugs Therapy

Request for Customization@ https://www.coherentmarketinsights.com/insight/request-customization/191

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tuberculosis Drugs Market High Funding for Research and Development and Growth by Pfizer Inc, Lupin Laboratories Ltd, AstraZeneca Plc, Cadila Pharmaceuticals, Novartis AG, Alkem Laboratories Ltd, and Cipla Ltd. here

News-ID: 1361574 • Views:

More Releases from Coherent Market Insights

Prebiotics for Dietary Supplements Market See Incredible Growth 2024-2031 | Clasado Biosciences, VW-Ingredients, Shandong Longli Biotechnology Co., Ltd, Prenexus Health., Ingredion, Tata Chemicals Ltd., Yakult Honsha Co., Ltd., Tate & Lyle, Roquette Frèr
Prebiotics for Dietary Supplements Market See Incredible Growth 2024-2031 | Clas …
Coherent Market Insights Published Most recent Prebiotics for Dietary Supplements Market Study by in-depth analysis of the current scenario, the Market size, demand, growth pattern, trends, and forecast. This report on the study considers important factors such as an analysis of the market, a definition of the market, market segmentation, significant trends in the industry, an examination of the competitive landscape, and research methodology. For achieving incredible growth in business,
DNA Repair Drugs Market Expected to Expand at a Steady 2024-2031 | AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., K
DNA Repair Drugs Market Expected to Expand at a Steady 2024-2031 | AstraZeneca P …
Coherent Market Insights Published Most recent DNA Repair Drugs Market Study by in-depth analysis of the current scenario, the Market size, demand, growth pattern, trends, and forecast. This report on the study considers important factors such as an analysis of the market, a definition of the market, market segmentation, significant trends in the industry, an examination of the competitive landscape, and research methodology. For achieving incredible growth in business, this
Polyethylene Terephthalate (PET) Market 2024-2031: Raw Materials Requirements, Manufacturing Process, Business Plan | Alpek S.A.B de C.V., RTP Company, BASF SE
Polyethylene Terephthalate (PET) Market 2024-2031: Raw Materials Requirements, M …
This comprehensive Report of the Polyethylene Terephthalate (PET) Market provides real information about the statistics and state of the global and regional market. Its scope study extends from the market situation to comparative pricing between the main players, spending in specific market areas, and profits. A complete and wide-ranging evaluation of the aspects that drive and restrain market growth is also provided throughout the study. This detailed exploration of the
Chlorine Market 2024-2031: Business Plan, Manufacturing Process, Machinery Requirement | BASF SE, Occidental Chemical Corporation
Chlorine Market 2024-2031: Business Plan, Manufacturing Process, Machinery Requi …
This comprehensive Report of the Chlorine Market provides real information about the statistics and state of the global and regional market. Its scope study extends from the market situation to comparative pricing between the main players, spending in specific market areas, and profits. A complete and wide-ranging evaluation of the aspects that drive and restrain market growth is also provided throughout the study. This detailed exploration of the market size

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug